Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Gynecologic 9 Gastrointestinal 7 Dermatologic 5 Head & Neck 4 Breast 4 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Lymphoid 1 Genitourinary 1 Endocrine 1 CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 130 Lenalidomide 82 daratumumab 60 Bortezomib 56 carfilzomib 45 Calcium Dobesilate 41 pomalidomide 37 Cyclophosphamide 31 isatuximab 26 belantamab mafodotin 23 Specimen Handling 21 Biopsy 21 Magnetic Resonance Spectroscopy 18 dexamethasone acetate 16 dexamethasone 21-phosphate 16 ixazomib 15 auricularum 15 fludarabine 13 Melphalan 13 iberdomide 11 elotuzumab 11 selinexor 10 fludarabine phosphate 9 X-Rays 8 talquetamab 7 venetoclax 6 trametinib 6 nirogacestat 6 Whole-Body Irradiation 6 Thalidomide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × dostarlimab × Plasma cell × Clear all

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡